Skyrizi and Multiple sclerosis - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Humira, and have Psoriasis.

The phase IV clinical study analyzes which people have Multiple sclerosis when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Multiple sclerosis?

Multiple sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,083 drugs and 1,366 conditions by eHealthMe. Check the latest studies of Multiple sclerosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 71 people (0.16%) have Multiple sclerosis.

Among these 71 people:

How long have people been on Skyrizi when they have Multiple sclerosis? *

What is the gender of people who have Multiple sclerosis when taking Skyrizi? *

female: 67.16 %
male: 32.84 %

What is the age of people who have Multiple sclerosis when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

What are other side effects people have besides Multiple sclerosis? *

Fall: 8 people, 11.27%
Psoriasis (immune-mediated disease that affects the skin): 7 people, 9.86%
Stress And Anxiety: 5 people, 7.04%
Weakness: 4 people, 5.63%
Itching: 4 people, 5.63%
Headache (pain in head): 4 people, 5.63%
Night Sweats (sweating in night): 4 people, 5.63%
Dizziness: 4 people, 5.63%
Nerve Injury: 4 people, 5.63%
Neurological Symptom (symptoms of nervous system disease): 3 people, 4.23%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 53 people, 74.65%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 10 people, 14.08%
Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 6 people, 8.45%
High Blood Pressure: 4 people, 5.63%
Depression: 3 people, 4.23%
High Blood Cholesterol: 2 people, 2.82%
Cardiac Disorder: 2 people, 2.82%
Thyroid Diseases: 1 person, 1.41%
Stress And Anxiety: 1 person, 1.41%
Pain: 1 person, 1.41%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Multiple sclerosis?

- Check whether Multiple sclerosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis:

Multiple sclerosis (1,083 drugs)

Browse all the conditions that are associated with Multiple sclerosis:

Multiple sclerosis (1,366 conditions)

Related publications that referenced our studies

Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .
Christopher KL, Elner VM, Demirci H, "Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis", Ophthalmic Plastic & Reconstructive Surgery, 2017 May .
Christopher, K. L., Elner, V. M., & Demirci, H. , "Conjunctival lymphoma in a patient on fingolimod for relapsing-remitting multiple sclerosis", Ophthalmic plastic and reconstructive surgery , 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.